Maastricht, The Netherlands (PRWEB) January 16, 2013
GlycoCheck B.V., a leading provider of imaging and measurement software of the endothelial glycocalyx layer, today announced a reseller partnership with U.S.-based Vascular Health Sciences.
Vascular Health Sciences will exclusively distribute GlycoCheck Vascular Health Monitor (VHM) in the United States. GlycoCheck VHM is a complete imaging solution for screening patients’ perfused boundary layer inside the blood vessels. The new technology measures and monitors changes in the glycocalyx layer non-invasively, accurately and in real time.
“We are pleased that Vascular Health Sciences has made a commitment to offer our GlycoCheck VHM solution to their customers throughout the United States,” said GlycoCheck CEO Pieter Goedhart.
GlycoCheck recently debuted in U.S. markets when Vascular Health Sciences attended the Age Management Medicine and Holistic Primary Care Conferences when doctors offered very favorable reviews of both GlycoCheck and Vascular Health Sciences’ all-natural artery health supplement, Arterosil.
“GlycoCheck provides a unique and novel technology to assess artery health in real time,” said Vascular Health Sciences Co-Founder and CEO Bob Long. “The more trials we conduct, both in the clinical setting and in a non-controlled conference setting, the more positive evidence we observe that proves Arterosil and Arterosil HP work. We’re thrilled to offer the benefits of this new technology to Health Care Practitioners and their patients.”
GlycoCheck is a leading provider of imaging solutions based on an innovative measurement system of the Glycocalyx layer. GlycoCheck solutions facilitate the accurate, reliable and non-invasive selection, detection & monitoring of patients in primary care, intensive care, cardiology
Copyright©2012 Vocus, Inc.
All rights reserved